Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 6Carcinoma, Non-Small-Cell Lung 6Stomach Neoplasms 5Lymphoma, Non-Hodgkin 5Carcinoma, Renal Cell 5Pancreatic Neoplasms 3Ovarian Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Colorectal Neoplasms 3Carcinoma, Merkel Cell 3Triple Negative Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 2Esophageal Neoplasms 2Carcinoma, Transitional Cell 2Adenocarcinoma of Lung 2Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Ovarian Cancer Metastatic 1Neuroblastoma 1Multiple Myeloma 1Microsatellite Instability 1Lymphoma, Follicular 1Lymphoma 1

Interventions

pembrolizumab 5atezolizumab 2Nivolumab 2fludarabine 1epacadostat 1durvalumab 1avelumab 1aldesleukin 1Interleukin-2 1Docetaxel 1Cyclophosphamide 1Carboxylesterase 1Bevacizumab 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Microsatellite Instability × aldesleukin × Clear all
NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡